文献速递造血干细胞移植与细胞治疗

供者调节性T细胞治疗预防移植物抗宿主病

Donor regulatory T-cell therapy to prevent graft-versus-host disease.
PubMed 文献 · Blood · 2025-01-01

这项开放标签、单中心、2期疗效研究纳入44例患者,评估供者动员外周血制备的精准选择高纯度Treg疗法在清髓性预处理后能否改善1年无GVHD无复发生存(GRFS),并与同期标准治疗队列比较。结果显示1年GRFS达64%,优于预期40%(P=0.002),标准治疗队列实际为36%;3-4级急性GVHD发生率7%,中重度慢性GVHD 11%,非复发死亡率4.5%。

要点

  • 供者Treg产品均在72小时内未冷冻保存即成功制备并输注。
  • 1年GRFS 64% vs 预期40%(P=0.002),标准治疗队列实际36%。
  • 3-4级急性GVHD 7%,中重度慢性GVHD 11%,非复发死亡率4.5%。

核心结论

  • 与高度可变未经处理供者移植物和多药免疫抑制的常见发生率相比,试验参与者GVHD发生率和负担降低、GRFS改善。

研究设计与样本

  • 开放标签、单中心、2期疗效研究,纳入44例患者,评估供者动员外周血制备的精准选择高纯度Treg疗法在清髓性预处理后改善1年GRFS的效果。
  • 与同期标准治疗(SOC)队列进行比较。

主要发现

  • 所有供者Treg产品均在72小时内未冷冻保存即成功制备并输注。
  • 1年3-4级急性GVHD发生率为7%,中重度慢性GVHD为11%,非复发死亡率为4.5%。
  • 主要终点1年GRFS显著改善,达64%,对照预期发生率40%(P=0.002),SOC队列实际发生率为36%。
  • 发生2-4级急性GVHD的试验患者中,91%对一线皮质类固醇治疗有反应,而SOC对照组为50%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic cell transplantation is a curative therapy limited by graft-versus-host disease (GVHD). In preclinical studies and early-phase clinical studies, enrichment of donor regulatory T cells (Tregs) appears to prevent GVHD and promote healthy immunity. We enrolled 44 patients in an open-label, single-center, phase 2 efficacy study investigating if a precision selected and highly purified Treg therapy manufactured from donor-mobilized peripheral blood improves 1-year GVHD-free relapse-free survival (GRFS) after myeloablative conditioning. We compared this study arm with a concomitant standard-of-care (SOC) cohort. All donor Treg products were successfully manufactured and administered without cryopreservation within 72 hours. Participants had a 1-year incidence of acute grade 3 to 4 GVHD of 7%, moderate to severe chronic GVHD of 11%, and nonrelapse mortality rate of 4.5%. The primary end point of significantly improved 1-year GRFS was achieved at 64% evaluated against a predicted incidence of 40% (P = .002) with a realized incidence of 36% in the SOC comparator. For those trial patients who developed grade 2 to 4 acute GVHD, 91% responded to front-line corticosteroid therapy, whereas 50% responded in the SOC comparator group. Trial participants had a reduced incidence and burden of GVHD and improved GRFS, compared with rates common to highly variable unmanipulated donor grafts and multiagent immune suppression. This trial was registered at www.clinicaltrials.gov as #NCT01660607.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Meyer EH, Pavlova A, Villar-Prados A, et al. Donor regulatory T-cell therapy to prevent graft-versus-host disease. Blood. 2025. PMID: 39792934. doi:10.1182/blood.2024026446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。